Sartorius (OTCMKTS:SARTF – Get Free Report) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 836 shares, a decline of 54.2% from the October 15th total of 1,827 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ? days. Currently, 0.0% of the shares of the stock are short sold.
Sartorius Stock Performance
SARTF stock remained flat at $261.99 during mid-day trading on Friday. Sartorius has a 12-month low of $181.58 and a 12-month high of $261.99. The firm has a fifty day moving average price of $241.61 and a 200-day moving average price of $224.03. The stock has a market cap of $8.97 billion, a P/E ratio of 121.85 and a beta of 0.98. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.95 and a quick ratio of 0.49.
About Sartorius
Sartorius is a life science company headquartered in Göttingen, Germany. Founded in 1870 as a precision-balance manufacturer, it has grown into a global supplier of technologies and services for biopharmaceutical production and laboratory research. The company’s bioprocessing products include filtration and fluid-management systems, single-use equipment, bioreactors, and technologies used in cell culture and purification. These solutions support the development and manufacture of biologic medicines, including vaccines and other advanced therapies.
Further Reading
- Five stocks we like better than Sartorius
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.
